-$0.06 EPS Expected for MiMedx Group, Inc. (NASDAQ:MDXG) This Quarter

Wall Street analysts expect that MiMedx Group, Inc. (NASDAQ:MDXGGet Rating) will post ($0.06) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for MiMedx Group’s earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at ($0.02). MiMedx Group posted earnings of ($0.03) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 100%. The firm is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that MiMedx Group will report full-year earnings of ($0.21) per share for the current financial year, with EPS estimates ranging from ($0.33) to ($0.08). For the next fiscal year, analysts forecast that the business will report earnings of ($0.01) per share, with EPS estimates ranging from ($0.21) to $0.29. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for MiMedx Group.

MiMedx Group (NASDAQ:MDXGGet Rating) last issued its earnings results on Tuesday, May 3rd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). During the same quarter in the previous year, the business earned ($0.09) earnings per share.

Separately, StockNews.com assumed coverage on MiMedx Group in a report on Thursday, March 31st. They issued a “buy” rating on the stock.

Shares of MDXG stock traded up $0.10 during trading hours on Tuesday, reaching $3.92. The company’s stock had a trading volume of 3,879 shares, compared to its average volume of 627,091. The firm’s 50 day simple moving average is $4.40 and its 200-day simple moving average is $5.46. The company has a market capitalization of $444.33 million, a price-to-earnings ratio of -23.00 and a beta of 1.92. MiMedx Group has a fifty-two week low of $3.27 and a fifty-two week high of $8.69. The company has a quick ratio of 3.35, a current ratio of 3.71 and a debt-to-equity ratio of 586.91.

In related news, CEO Timothy R. Wright sold 61,000 shares of the firm’s stock in a transaction on Wednesday, February 23rd. The stock was sold at an average price of $4.31, for a total transaction of $262,910.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Scott M. Turner sold 5,738 shares of the firm’s stock in a transaction on Wednesday, February 23rd. The shares were sold at an average price of $4.50, for a total value of $25,821.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 195,076 shares of company stock worth $890,004. 19.80% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in MDXG. Morgan Stanley lifted its holdings in MiMedx Group by 194.5% during the 2nd quarter. Morgan Stanley now owns 207,066 shares of the company’s stock worth $2,590,000 after buying an additional 136,754 shares during the period. Wells Fargo & Company MN lifted its holdings in MiMedx Group by 47.8% during the 2nd quarter. Wells Fargo & Company MN now owns 25,098 shares of the company’s stock worth $314,000 after buying an additional 8,115 shares during the period. SG Americas Securities LLC acquired a new position in MiMedx Group during the 3rd quarter worth about $344,000. State Board of Administration of Florida Retirement System lifted its holdings in MiMedx Group by 263.8% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 53,443 shares of the company’s stock worth $324,000 after buying an additional 38,751 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in MiMedx Group by 18.7% during the 3rd quarter. Principal Financial Group Inc. now owns 19,130 shares of the company’s stock worth $116,000 after buying an additional 3,010 shares during the period. 60.31% of the stock is currently owned by hedge funds and other institutional investors.

About MiMedx Group (Get Rating)

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

Further Reading

Get a free copy of the Zacks research report on MiMedx Group (MDXG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.